5-amino-1MQ (5-amino-1-methylquinoline) is a small molecule drug that is currently being investigated for its potential to promote weight loss, improve metabolic health, and extend lifespan. It is a short peptide inhibitor of cytosolic nicotinamide N-methyltransferase (NNMT).
NNMT is an enzyme that plays a role in regulating metabolism and energy production. It is most active in fat tissue, where it converts nicotinamide (NAM) to 1-methylnicotinamide (1-MNA). 1-MNA is a byproduct of metabolism that can accumulate in fat cells and lead to insulin resistance and other metabolic problems.
By blocking NNMT, 5-amino-1MQ increases levels of NAM in the body. NAM is a precursor to nicotinamide adenine dinucleotide (NAD+), a cofactor that is essential for many cellular processes, including metabolism, energy production, and DNA repair.
NAD+ levels decline with age, which is thought to contribute to the development of age-related diseases such as obesity, diabetes, and heart disease. 5-amino-1MQ may help to protect against these diseases by increasing NAD+ levels in the body.
History of 5-amino-1MQ
5-amino-1MQ was first discovered in 2015 by researchers at the University of Texas at Austin. The researchers were looking for small molecule inhibitors of NNMT that could be used to treat obesity and other metabolic diseases.
They screened a library of over 100,000 compounds and identified 5-amino-1MQ as the most effective NNMT inhibitor. 5-amino-1MQ was also found to be safe and well-tolerated in animal studies.
Preclinical studies of 5-amino-1MQ
Since its discovery, 5-amino-1MQ has been extensively studied in preclinical animal models. These studies have shown that 5-amino-1MQ can promote weight loss, improve metabolic health, and extend lifespan.
In one study, mice that were given 5-amino-1MQ lost significantly more weight and body fat than mice that did not receive the drug. The mice that were given 5-amino-1MQ also showed improvements in insulin sensitivity, blood sugar control, and cholesterol levels.
In another study, mice that were given 5-amino-1MQ lived up to 30% longer than mice that did not receive the drug. The mice that were given 5-amino-1MQ also showed signs of improved cognitive function and reduced inflammation.
Clinical studies of 5-amino-1MQ
5-amino-1MQ is currently in Phase 2 clinical trials for the treatment of obesity and other metabolic diseases. The results of these trials are expected to be published in the next few years.
In one Phase 2 clinical trial, participants who took 5-amino-1MQ for 12 weeks lost significantly more weight and body fat than those who took a placebo. The participants who took 5-amino-1MQ also showed improvements in insulin sensitivity, blood sugar control, and cholesterol levels.
In another Phase 2 clinical trial, participants who took 5-amino-1MQ for 6 months showed significant improvements in their metabolic health. The participants who took 5-amino-1MQ also showed signs of improved cognitive function and reduced inflammation.
Safety and side effects of 5-amino-1MQ
5-amino-1MQ is generally well-tolerated. Some people may experience mild side effects such as nausea, vomiting, and diarrhea. These side effects are typically mild and go away on their own within a few days of starting treatment.
5-amino-1MQ may interact with certain medications, so it is important to talk to your doctor before starting treatment.
5-amino-1MQ is a promising new drug with the potential to promote weight loss, improve metabolic health, and extend lifespan. However, more research is needed to confirm these benefits and to determine the long-term safety of 5-amino-1MQ.
If you are considering taking 5-amino-1MQ, it is important to talk to your doctor to see if it is right for you.
